Axa Invests $3.71 Million in Stemline Therapeutics Inc (STML)
Axa bought a new position in shares of Stemline Therapeutics Inc (NASDAQ:STML) during the first quarter, Holdings Channel reports. The fund bought 434,183 shares of the biopharmaceutical company’s stock, valued at approximately $3,712,000.
Other large investors have also recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. boosted its stake in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in Stemline Therapeutics during the third quarter worth approximately $2,783,000. State Street Corp boosted its stake in Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock worth $2,694,000 after buying an additional 21,296 shares during the last quarter. Finally, J. Goldman & Co LP purchased a new stake in Stemline Therapeutics during the fourth quarter worth approximately $2,139,000. 37.76% of the stock is owned by institutional investors.
Stemline Therapeutics Inc (NASDAQ:STML) remained flat at $7.65 on Friday. The company’s stock had a trading volume of 57,602 shares. The firm’s market cap is $178.83 million. The stock has a 50-day moving average of $8.30 and a 200-day moving average of $9.50. Stemline Therapeutics Inc has a 52 week low of $5.50 and a 52 week high of $14.60.
Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.22. Stemline Therapeutics had a negative return on equity of 50.06% and a negative net margin of 4,058.44%. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.30 million. Analysts forecast that Stemline Therapeutics Inc will post ($2.26) earnings per share for the current year.
STML has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, March 28th. Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 9th. Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Stemline Therapeutics in a research report on Friday, March 17th. Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a research report on Friday, May 12th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Stemline Therapeutics in a report on Thursday, May 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $29.17.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics Inc (NASDAQ:STML).
Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.